Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
about
Follicular lymphoma: 2012 update on diagnosis and managementBendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaRituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaBendamustine for patients with B cell lymphoid malignanciesMonoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaFollicular lymphoma: 2011 update on diagnosis and managementBendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient managementPharmacokinetic and pharmacodynamic profile of bendamustine and its metabolitesFollicular lymphoma: 2014 update on diagnosis and managementTreatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsPurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesLong-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.Current and emerging therapies in mantle cell lymphoma.Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphomaTreatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphomaSafety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.Bendamustine salvage therapy for T cell neoplasms.Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.Role of bendamustine in the treatment of chronic lymphocytic leukemia.Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab.Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancyThe role of bendamustine in the treatment of indolent non-Hodgkin lymphomaPhase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBendamustine: safety and efficacy in the management of indolent non-hodgkins lymphomaNovel therapeutics for aggressive non-Hodgkin's lymphoma.Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.
P2860
Q22252956-4E28CF34-F3EB-4D01-9D4A-5A0F10B61F9BQ24200280-81D7164E-E584-4C1A-BEED-0245A4D13065Q24203027-10B73595-CB9F-4258-BCAC-D3CDB0A18A2CQ24236426-F3E8125B-98A0-46F4-98B3-1CB880828C07Q24241519-77AC2435-6DEB-4B4E-B8D3-D009CEA35A5AQ26851450-9F0CE636-ED25-4F65-8393-540183F80729Q27002428-B91F439F-AE14-43CB-8648-ECBD5DFAAE84Q27011795-5AEA75C7-D92D-488D-AFD9-54E1E8D996F9Q27021850-1187DC93-139A-41C9-8A88-C61069C1E6CCQ27693252-A0E5F389-3C87-44CD-A6CD-BC9E21AEC14EQ28075606-428107D4-6597-4218-BABF-69D274453ACDQ28540830-7EE85A24-1107-40A2-8CEF-D47C3FE8F230Q30252598-51EAA524-826B-4270-9A4C-5F3488452FEFQ30435188-4A703125-8B5F-4147-B48C-D4E82B15D852Q30456545-1FE4D64C-8F92-4678-B0DC-CFBB0B4DBA63Q33394023-F22CE157-B329-43D8-86B6-209073BDFC69Q33394623-CA81771C-A53E-488B-967B-C0745FFB601CQ33394853-8C3FFE11-A0B9-4334-8AD3-1FD0733F281AQ33395564-FF422FBE-0ADA-4F38-8C22-43831EF5753FQ33398818-87496DF1-B838-4CFF-AC78-D3969800086CQ33405150-140489F1-BE22-431F-B4AC-878FAE673214Q33407099-29642A29-7391-44AA-9260-9D96A62DFC7AQ33409149-CCE1874F-9C72-4C44-99FB-F9BF62DF5494Q33410064-CA105BA3-902B-4651-A73F-9F761CE5A68FQ33421147-9142526C-315B-42FA-8E11-767390D92CB0Q33440251-9CDE4860-84E5-421E-BD32-145DD295A3ABQ33656746-B246FE6D-A60A-4266-8579-B3D076D3390AQ33730841-283E1E7C-778B-4180-BE42-432A47440D46Q33877999-5D44BF86-8DC0-4D55-B3EB-C764A1859B6EQ33916026-DF9123CE-4BCE-4FE4-86B7-D037482B2A31Q34181244-002B2A5C-4FB2-4C41-964E-3CDC04A8CA3DQ34322781-992D42BE-9077-4E81-AC1D-B69A3C016EFEQ34418442-EB5C7188-58DE-4CA7-9859-B5208415CB1BQ34498655-CA706E60-9814-4A6F-9DE1-1581ED7AE4C4Q34619308-3161341E-AA97-4A92-952B-BEB0B6675ACBQ34663603-16A3BFC6-8A9F-4435-8C11-4815C492656EQ34707136-317104B9-5C3D-4977-9CF2-332672DA2922Q35052538-43D449BA-3C53-4EC8-B346-BE3FD227C0C1Q35111768-696D3CA8-D930-48D8-816E-31F007C6C3CDQ35205349-0B6A60AF-2409-4504-8AC4-604B50A3A314
P2860
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase II multicenter study of ...... e cell non-Hodgkin's lymphoma.
@ast
Phase II multicenter study of ...... e cell non-Hodgkin's lymphoma.
@en
type
label
Phase II multicenter study of ...... e cell non-Hodgkin's lymphoma.
@ast
Phase II multicenter study of ...... e cell non-Hodgkin's lymphoma.
@en
prefLabel
Phase II multicenter study of ...... e cell non-Hodgkin's lymphoma.
@ast
Phase II multicenter study of ...... e cell non-Hodgkin's lymphoma.
@en
P2093
P356
P1476
Phase II multicenter study of ...... e cell non-Hodgkin's lymphoma.
@en
P2093
Anil Tulpule
Bernard Lemieux
Bruce D Cheson
Jordan A Herst
K Sue Robinson
Lee S Schwartzberg
Michael E Williams
Philip Cohen
Richard H van der Jagt
P304
P356
10.1200/JCO.2008.17.0001
P407
P577
2008-07-14T00:00:00Z